I-DXd (B7-H3-directed ADC), HER3-DXd (HER3-directed ADC), and R-DXd (CDH6-directed ADC). Daiichi Sankyo's environmental, social, and governance risks are included in our valuation. Like any other ...
Sales of Daiichi Sankyo ... with HER3-DXd in breast cancer. Next slide. Now we're going to switch over to the I-DXd program. This is also formerly known as DS-7300 where the ADC is targeting ...
Bernstein analyst Miki Sogi maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research ... such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting ... advanced non-squamous NSCLC. The HER3-directed ADC will be tested in patients whose ...
is a HER3-targeted ADC in late-stage clinical testing for lung cancer. Together, the three ADCs are billed as one of the strategic pillars of Daiichi Sankyo's current five-year business plan to 2025.
TROPION-Lung10 is evaluating Daiichi Sankyo and ... TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 ...
Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE ... Patritumab deruxtecan (HER3-DXd), a HER3 directed ...
Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568 ... Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ...
TROPION-Lung10 is evaluating Daiichi Sankyo and ... a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally with ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...